US4277437A
(en)
|
1978-04-05 |
1981-07-07 |
Syva Company |
Kit for carrying out chemically induced fluorescence immunoassay
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
US5200313A
(en)
|
1983-08-05 |
1993-04-06 |
Miles Inc. |
Nucleic acid hybridization assay employing detectable anti-hybrid antibodies
|
US4683196A
(en)
|
1983-12-12 |
1987-07-28 |
Meru, Inc. |
Method and materials for the identification of lipopolysaccharide producing microorganisms
|
US4777245A
(en)
|
1984-01-06 |
1988-10-11 |
Genelabs Incorporated |
Non-human primate monoclonal antibodies and methods
|
US4921698A
(en)
|
1984-05-25 |
1990-05-01 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Polypeptide having gamma-interferon activity lacking amino acids coded by exon 4
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
EP0228458B2
(en)
|
1985-07-05 |
1997-10-22 |
Whitehead Institute For Biomedical Research |
Epithelial cells expressing foreign genetic material
|
US4980286A
(en)
|
1985-07-05 |
1990-12-25 |
Whitehead Institute For Biomedical Research |
In vivo introduction and expression of foreign genetic material in epithelial cells
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
US5116742A
(en)
|
1986-12-03 |
1992-05-26 |
University Patents, Inc. |
RNA ribozyme restriction endoribonucleases and methods
|
US5073492A
(en)
|
1987-01-09 |
1991-12-17 |
The Johns Hopkins University |
Synergistic composition for endothelial cell growth
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
EP0378576B1
(en)
|
1987-09-11 |
1995-01-18 |
Whitehead Institute For Biomedical Research |
Transduced fibroblasts and uses therefor
|
WO1989005345A1
(en)
|
1987-12-11 |
1989-06-15 |
Whitehead Institute For Biomedical Research |
Genetic modification of endothelial cells
|
JP2917998B2
(ja)
|
1988-02-05 |
1999-07-12 |
ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ |
修飾された肝細胞およびその用途
|
JP2650159B2
(ja)
|
1988-02-24 |
1997-09-03 |
アクゾ・ノベル・エヌ・ベー |
核酸増幅方法
|
CA1340807C
(en)
|
1988-02-24 |
1999-11-02 |
Lawrence T. Malek |
Nucleic acid amplification process
|
US5130238A
(en)
|
1988-06-24 |
1992-07-14 |
Cangene Corporation |
Enhanced nucleic acid amplification process
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5527681A
(en)
|
1989-06-07 |
1996-06-18 |
Affymax Technologies N.V. |
Immobilized molecular synthesis of systematically substituted compounds
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
NZ235148A
(en)
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
US5545522A
(en)
|
1989-09-22 |
1996-08-13 |
Van Gelder; Russell N. |
Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
US5744500A
(en)
|
1990-01-03 |
1998-04-28 |
Teva Pharmaceutical Industries, Ltd. |
Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
|
US6013431A
(en)
|
1990-02-16 |
2000-01-11 |
Molecular Tool, Inc. |
Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
|
AT396939B
(de)
|
1990-05-29 |
1993-12-27 |
Alois Dipl Ing Dr Jungbauer |
Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
|
US5387742A
(en)
|
1990-06-15 |
1995-02-07 |
Scios Nova Inc. |
Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
AU656544B2
(en)
|
1990-10-31 |
1995-02-09 |
Brigham And Women's Hospital |
Genetic modification of endothelial cells
|
ATE286971T1
(de)
|
1991-01-21 |
2005-01-15 |
Elan Pharm Inc |
Prüfung und modell für alzheimers-krankheit
|
US5455166A
(en)
|
1991-01-31 |
1995-10-03 |
Becton, Dickinson And Company |
Strand displacement amplification
|
AU675916B2
(en)
|
1991-06-14 |
1997-02-27 |
Genentech Inc. |
Method for making humanized antibodies
|
US5384261A
(en)
|
1991-11-22 |
1995-01-24 |
Affymax Technologies N.V. |
Very large scale immobilized polymer synthesis using mechanically directed flow paths
|
ATE408012T1
(de)
|
1991-12-02 |
2008-09-15 |
Medical Res Council |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
CA2127450C
(en)
|
1992-01-07 |
2007-04-17 |
Samuel Wadsworth |
Transgenic animal models for alzheimer's disease
|
US5604102A
(en)
|
1992-04-15 |
1997-02-18 |
Athena Neurosciences, Inc. |
Methods of screening for β-amyloid peptide production inhibitors
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
US5288514A
(en)
|
1992-09-14 |
1994-02-22 |
The Regents Of The University Of California |
Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
AU688751B2
(en)
|
1993-01-12 |
1998-03-19 |
Biogen Idec Ma Inc. |
Recombinant anti-VLA4 antibody molecules
|
US5714320A
(en)
|
1993-04-15 |
1998-02-03 |
University Of Rochester |
Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides
|
US5422252A
(en)
|
1993-06-04 |
1995-06-06 |
Becton, Dickinson And Company |
Simultaneous amplification of multiple targets
|
CA2174429C
(en)
|
1993-10-27 |
2011-08-30 |
Lisa C. Mcconlogue |
Transgenic animals harboring app allele having swedish mutation
|
WO1995014772A1
(fr)
|
1993-11-12 |
1995-06-01 |
Kenichi Matsubara |
Signature genique
|
JPH07132033A
(ja)
|
1993-11-12 |
1995-05-23 |
Hoechst Japan Ltd |
アルツハイマー病モデルトランスジェニック動物
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US5877399A
(en)
|
1994-01-27 |
1999-03-02 |
Johns Hopkins University |
Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
|
JP3175110B2
(ja)
|
1994-02-07 |
2001-06-11 |
オーキッド・バイオサイエンシーズ・インコーポレイテッド |
リガーゼ/ポリメラーゼ媒体された単一ヌクレオチド多型のジェネティックビットアナリシスおよび遺伝子解析におけるその使用
|
WO2000037638A2
(en)
|
1998-12-22 |
2000-06-29 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
US20030198640A1
(en)
|
1994-11-07 |
2003-10-23 |
Human Genome Sciences, Inc. |
Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
|
JPH10510986A
(ja)
|
1994-12-13 |
1998-10-27 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
メタロプロテイナーゼ−4のヒト組織インヒビター
|
US6544761B2
(en)
|
1994-12-13 |
2003-04-08 |
Human Genome Sciences, Inc. |
Human tissue inhibitor of metalloproteinase-4
|
AU2466895A
(en)
|
1995-04-28 |
1996-11-18 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
CA2229043C
(en)
|
1995-08-18 |
2016-06-07 |
Morphosys Gesellschaft Fur Proteinoptimierung Mbh |
Protein/(poly)peptide libraries
|
US5733729A
(en)
|
1995-09-14 |
1998-03-31 |
Affymetrix, Inc. |
Computer-aided probability base calling for arrays of nucleic acid probes on chips
|
DE19541844C1
(de)
|
1995-11-09 |
1997-07-24 |
Gsf Forschungszentrum Umwelt |
Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
|
AU714486B2
(en)
|
1995-11-21 |
2000-01-06 |
Yale University |
Unimolecular segment amplification and detection
|
US5854033A
(en)
|
1995-11-21 |
1998-12-29 |
Yale University |
Rolling circle replication reporter systems
|
US20030143204A1
(en)
|
2001-07-27 |
2003-07-31 |
Lewis David L. |
Inhibition of RNA function by delivery of inhibitors to animal cells
|
BRPI9715219B8
(pt)
|
1996-02-09 |
2015-07-07 |
Abbvie Biotechnology Ltd |
Vetor recombinante de expressão, e célula hospedeira procariótica.
|
US5894078A
(en)
|
1996-02-26 |
1999-04-13 |
Advanced Bioconcept, Inc. |
Transgenic mouse expressing C-100 app
|
WO1997035033A1
(en)
|
1996-03-19 |
1997-09-25 |
Molecular Tool, Inc. |
Method for determining the nucleotide sequence of a polynucleotide
|
US7129061B1
(en)
*
|
1996-08-07 |
2006-10-31 |
Biogen Idec Ma Inc. |
Tumor necrosis factor related ligand
|
EP0956351B1
(en)
|
1996-08-07 |
2005-10-19 |
Biogen Idec MA Inc. |
A tumor necrosis factor related ligand
|
GB9618050D0
(en)
|
1996-08-29 |
1996-10-09 |
Cancer Res Campaign Tech |
Global amplification of nucleic acids
|
US5898094A
(en)
|
1996-10-21 |
1999-04-27 |
University Of South Florida |
Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
|
AU5702298A
(en)
|
1996-12-03 |
1998-06-29 |
Abgenix, Inc. |
Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
|
US5858991A
(en)
|
1997-01-29 |
1999-01-12 |
Vanderbilt University |
Facilitation of wound healing with CM101/GBS toxin
|
WO1998035061A2
(en)
|
1997-02-12 |
1998-08-13 |
Abbott Laboratories |
Member of the tnf family useful for treatment and diagnosis of disease
|
US7368531B2
(en)
*
|
1997-03-07 |
2008-05-06 |
Human Genome Sciences, Inc. |
Human secreted proteins
|
DE69833755T2
(de)
|
1997-05-21 |
2006-12-28 |
Biovation Ltd. |
Verfahren zur herstellung von nicht-immunogenen proteinen
|
ATE487737T1
(de)
|
1997-05-30 |
2010-11-15 |
Human Genome Sciences Inc |
32 humane sekretierte proteine
|
US7001992B2
(en)
|
1997-05-30 |
2006-02-21 |
Human Genome Sciences, Inc. |
Antibodies to secreted protein HEMCM42
|
JP2002512524A
(ja)
|
1997-06-03 |
2002-04-23 |
財団法人相模中央化学研究所 |
膜貫通ドメインを有するヒト蛋白質及びそれをコードするdna
|
AU9376498A
(en)
|
1997-09-05 |
1999-03-22 |
University Of Washington |
Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
|
ATE393222T1
(de)
|
1997-09-18 |
2008-05-15 |
Genentech Inc |
Dcr3 polypeptid, ein tnfr homolog
|
ATE424459T1
(de)
|
1997-10-10 |
2009-03-15 |
Genentech Inc |
Apo-3 ligand
|
US20020072089A1
(en)
|
1999-11-23 |
2002-06-13 |
Holtzman Douglas A. |
Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor
|
US6046381A
(en)
|
1998-04-30 |
2000-04-04 |
The Regents Of The University Of California |
Apolipoprotein E transgenic mice and assay methods
|
AU4672199A
(en)
|
1998-05-20 |
1999-12-06 |
Yale University |
Modulation of angiogenesis and wound healing
|
WO1999061471A2
(en)
|
1998-05-29 |
1999-12-02 |
Incyte Pharmaceuticals, Inc. |
Human transmembrane proteins
|
CA2345382A1
(en)
|
1998-10-16 |
2000-04-27 |
Immunex Corporation |
Inhibitors of platelet activation and recruitment
|
CN1202128C
(zh)
|
1998-12-08 |
2005-05-18 |
拜奥威神有限公司 |
修饰蛋白的免疫原性
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
HUP0105044A3
(en)
*
|
1999-01-15 |
2004-07-28 |
Biogen Inc Cambridge |
Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
|
WO2000044777A1
(en)
|
1999-01-29 |
2000-08-03 |
Imclone Systems Incorporated |
Antibodies specific to kdr and uses thereof
|
US6946293B1
(en)
|
1999-02-10 |
2005-09-20 |
Es Cell International Pte Ltd. |
Progenitor cells, methods and uses related thereto
|
US20020004041A1
(en)
|
1999-02-19 |
2002-01-10 |
Albert Matthew L. |
Methods for abrogating a cellular immune response
|
ATE364628T1
(de)
|
1999-03-08 |
2007-07-15 |
Genentech Inc |
Verfahren und zusammensetzungen zur diagnose von tumoren
|
US6132997A
(en)
|
1999-05-28 |
2000-10-17 |
Agilent Technologies |
Method for linear mRNA amplification
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
KR100510795B1
(en)
*
|
1999-08-31 |
2005-08-30 |
|
Compositions and Methods for the Treatment of Tumor
|
CA2394015C
(en)
*
|
1999-12-20 |
2013-11-05 |
Immunex Corporation |
Tweak receptor
|
US7495086B2
(en)
*
|
1999-12-20 |
2009-02-24 |
Immunex Corporation |
TWEAK receptor
|
US6727225B2
(en)
*
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
AU2926401A
(en)
|
2000-01-03 |
2001-07-16 |
Tr Associates, L.L.C. |
Novel chimeric proteins and methods for using the same
|
US7927602B2
(en)
|
2002-07-23 |
2011-04-19 |
University Of Louisville Research Foundation, Inc. |
Fas ligand-avidin/streptavidin fusion proteins
|
JP2003520852A
(ja)
|
2000-01-27 |
2003-07-08 |
アメリカン・サイアナミド・カンパニー |
α−スルホニルヒドロキサム酸誘導体を製造する方法
|
CA2400040A1
(en)
|
2000-02-25 |
2001-08-30 |
Immunex Corporation |
Integrin antagonists
|
US6608048B2
(en)
|
2000-03-28 |
2003-08-19 |
Wyeth Holdings |
Tricyclic protein kinase inhibitors
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
AU2001257331A1
(en)
|
2000-04-28 |
2001-11-12 |
Sangamo Biosciences, Inc. |
Methods for designing exogenous regulatory molecules
|
WO2001085193A2
(en)
|
2000-05-08 |
2001-11-15 |
Biogen, Inc. |
Method for promoting neovascularization using a tweak agonist and an angiogenic factor
|
JP2004503958A
(ja)
|
2000-06-15 |
2004-02-05 |
三菱電機株式会社 |
優先ネットワーク接続を判定するための入札機構
|
US7498304B2
(en)
|
2000-06-16 |
2009-03-03 |
Curis, Inc. |
Angiogenesis-modulating compositions and uses
|
US20040047854A1
(en)
|
2001-07-27 |
2004-03-11 |
Black Roy A. |
Human disintegrin protein
|
NZ525140A
(en)
|
2000-09-14 |
2005-10-28 |
Biogen Idec Inc |
Tweak receptor and Fn14 agonists as anti-angiogenic agents
|
US7208151B2
(en)
|
2001-09-12 |
2007-04-24 |
Biogen Idec Ma Inc. |
Tweak receptor agonists as anti-angiogenic agents
|
US7175849B2
(en)
*
|
2000-10-05 |
2007-02-13 |
Immunex Corporation |
Nectin polypeptides
|
JP4344519B2
(ja)
|
2000-12-28 |
2009-10-14 |
旭化成ファーマ株式会社 |
NF−κB活性化遺伝子
|
EP1379264A4
(en)
|
2001-03-21 |
2009-07-08 |
Human Genome Sciences Inc |
HUMAN SECRETED PROTEINS
|
US20040253637A1
(en)
|
2001-04-13 |
2004-12-16 |
Biosite Incorporated |
Markers for differential diagnosis and methods of use thereof
|
US20040203083A1
(en)
*
|
2001-04-13 |
2004-10-14 |
Biosite, Inc. |
Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
|
IL159015A0
(en)
|
2001-05-25 |
2004-05-12 |
Genset Sa |
Polypeptides, their preparation and use
|
US20040076955A1
(en)
|
2001-07-03 |
2004-04-22 |
Eos Biotechnology, Inc. |
Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
|
US20040091473A1
(en)
|
2001-07-27 |
2004-05-13 |
Dubose Robert F. |
Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
|
AU2002363354A1
(en)
*
|
2001-07-27 |
2003-05-19 |
Human Genome Sciences, Inc. |
Heteromultimeric tnf ligand family members
|
US20030148314A1
(en)
|
2001-08-01 |
2003-08-07 |
Millennium Pharmaceuticals, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
|
US20040033495A1
(en)
|
2001-08-03 |
2004-02-19 |
Eos Biotechnology, Inc. |
Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
|
US7087225B2
(en)
|
2001-08-16 |
2006-08-08 |
Human Genome Sciences, Inc. |
Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
|
EP2067472A1
(en)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP1572902B1
(en)
|
2002-02-01 |
2014-06-11 |
Life Technologies Corporation |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
CN1658901A
(zh)
*
|
2002-04-09 |
2005-08-24 |
比奥根艾迪克Ma公司 |
用于治疗tweak相关病症的方法
|
AU2003234336A1
(en)
|
2002-05-03 |
2003-11-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for use in preparing sirnas
|
US7628988B2
(en)
|
2002-06-27 |
2009-12-08 |
The General Hospital Corporation |
Methods and compositions for treating type 1 diabetes
|
DE60328214D1
(de)
|
2002-08-12 |
2009-08-13 |
New England Biolabs Inc |
Verfahren und zusammensetzungen in verbindung mit gen-silencing
|
US7754884B2
(en)
|
2005-01-03 |
2010-07-13 |
Vanderbilt University |
Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging
|
ES2897506T3
(es)
|
2003-01-09 |
2022-03-01 |
Macrogenics Inc |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
|
WO2004063355A2
(en)
|
2003-01-10 |
2004-07-29 |
Protein Design Labs, Inc. |
Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
|
US20050079574A1
(en)
|
2003-01-16 |
2005-04-14 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
WO2004074433A2
(en)
|
2003-01-30 |
2004-09-02 |
Yale University |
Rag polypeptides, nucleic acids, and their use
|
WO2004074506A2
(en)
|
2003-02-13 |
2004-09-02 |
Mergen Ltd |
Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
|
US20050008625A1
(en)
|
2003-02-13 |
2005-01-13 |
Kalobios, Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
WO2004079014A2
(en)
|
2003-03-04 |
2004-09-16 |
Arcturus Bioscience, Inc. |
Signatures of er status in breast cancer
|
US20050143297A1
(en)
|
2003-05-26 |
2005-06-30 |
Jean-Pierre Rosat |
Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity
|
EP1648936B1
(en)
|
2003-07-24 |
2007-06-06 |
Amgen Inc. |
Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor
|
WO2005053728A2
(de)
|
2003-12-01 |
2005-06-16 |
Xantos Biomedicine Ag |
Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
|
EP1566636A1
(en)
|
2004-02-23 |
2005-08-24 |
AXARON Bioscience AG |
Use of Tweak modulators and inhibitors for the treatment of neurological conditions
|
SV2006002131A
(es)
|
2004-06-04 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento de lupus
|
CA2587018A1
(en)
|
2004-11-08 |
2006-05-18 |
University Of Maryland, Baltimore |
Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
|
US7939490B2
(en)
*
|
2004-12-13 |
2011-05-10 |
University Of Maryland, Baltimore |
TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
|
US20090068102A1
(en)
|
2005-02-17 |
2009-03-12 |
Biogen Idec Ma Inc. |
Treating stroke
|
WO2006089095A2
(en)
|
2005-02-17 |
2006-08-24 |
Biogen Idec Ma Inc. |
Treating neurological disorders
|
CA2597485A1
(en)
|
2005-03-07 |
2006-09-14 |
Genentech, Inc. |
Methods and compositions for modulating tweak and fn14 activity
|
EP1885388B1
(en)
|
2005-05-10 |
2013-09-11 |
Biogen Idec MA Inc. |
Treating and evaluating inflammatory disorders
|
WO2006125632A2
(en)
|
2005-05-24 |
2006-11-30 |
Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh |
Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
|
EP1764109A1
(de)
|
2005-05-24 |
2007-03-21 |
Xantos Biomedicine AG |
Agonistische Antikörper, welche an den Tweak Rezeptor Fn14 binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
|
NZ583636A
(en)
|
2005-05-27 |
2011-12-22 |
Biogen Idec Inc |
Tweak binding antibodies
|
WO2006130429A2
(en)
|
2005-05-27 |
2006-12-07 |
Biogen Idec Ma Inc. |
Treatment of cancer
|
WO2006138219A2
(en)
|
2005-06-13 |
2006-12-28 |
Biogen Idec Ma Inc. |
Methods of diagnosis / prognosis of inflammatory conditions
|
WO2008048924A2
(en)
|
2006-10-16 |
2008-04-24 |
Biogen Idec Ma Inc. |
Biomarkers of multiple sclerosis
|
MX2010001378A
(es)
|
2007-08-03 |
2010-06-02 |
Facet Biotech Corp |
Uso terapeutico de anticuerpos del receptor anti-tweak.
|
US20120301444A1
(en)
|
2007-09-27 |
2012-11-29 |
Clarke Diana L |
Amnion-derived cell compositions, methods of making and uses thereof
|
AU2009246640A1
(en)
|
2008-05-15 |
2009-11-19 |
Biogen Idec Ma Inc. |
Anti-Fn14 antibodies and uses thereof
|
WO2010085648A2
(en)
|
2009-01-23 |
2010-07-29 |
Linda Burkly C |
Methods for reducing radiation-induced tissue damage
|
MX2011007936A
(es)
|
2009-01-30 |
2011-08-17 |
Biogen Idec Inc |
Metodos para regeneracion de tejido pancreatico.
|
WO2011084714A2
(en)
|
2009-12-17 |
2011-07-14 |
Biogen Idec Ma Inc. |
STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
|
WO2011097500A2
(en)
|
2010-02-04 |
2011-08-11 |
University Of Louisville Research Foundation, Inc. |
The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
|
MX343114B
(es)
|
2010-10-05 |
2016-10-25 |
F Hoffmann-La Roche Ag * |
Anticuerpos contra la tweak humana y usos de los mismos.
|
US20160243224A1
(en)
|
2013-10-04 |
2016-08-25 |
Biogen Ma Inc. |
Tweak antagonists for treating lupus nephritis and muscle atrophy
|
JP2016031772A
(ja)
|
2014-07-30 |
2016-03-07 |
株式会社日立ハイテクファインシステムズ |
熱アシスト磁気ヘッド素子の検査方法及びその装置
|